DIA, a neutral, global, professional and member-driven association of nearly 18,000 professionals, announced the arrival of Stephen P. Spielberg, M.D., Ph.D., as editor-in-chief of the newly launched, official DIA peer-reviewed scientific journal, Therapeutic Innovation & Regulatory Science (TIRS).
Spielberg comes to DIA on the heels of his tenure at the FDA, where he has served since September 2011 as deputy commissioner for medical products and tobacco. With a career spanning more than 35 years in medicine, academia, the pharmaceutical industry and regulatory affairs, Spielberg brings experience and leadership to DIA's journal. Spielberg formerly served as executive director of exploratory biochemical toxicology and of clinical and regulatory development at Merck Research Laboratories, and was vice president for pediatric drug development at Johnson & Johnson.
More recently, he was the chair in pediatric pharmacogenomics and director of the Center for Personalized Medicine and Therapeutic Innovation at Children's Mercy Hospital, Kansas City, Mo., as well as the dean of Dartmouth Medical School and vice president for health affairs at Dartmouth College. Spielberg also served on the board of directors of the Foundation for the National Institutes of Health, the FDA science board advisory committee and the executive board of Observational Medical Outcomes Partnership. Spielberg also brings a wealth of editorial experience to DIA. He previously was associate editor of Drug Metabolism and Disposition and serves on the editorial boards of multiple pediatric and pharmacology journals.